1 Final Shot for Hyped Alzheimer's Drug

Alzheimer's disease has been incredibly frustrating for the pharmaceutical industry. Decades of R&D have left little to show for the time and money spent. Designing successful treatments for a $600 billion worldwide problem (including dementia) is difficult when scientists don't totally understand what causes it. Eli Lilly is hoping to change that after announcing details around a new phase 3 trial for solanezumab.

In this video, health-care analyst David Williamson discusses Eli Lilly's struggle to combat Alzheimer's, how investors should react to today's news, and where it leaves Eli Lilly's stock going forward.

Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may affect your taxes, health insurance, and investments. Click here for your free copy today.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 14, 2013, at 6:24 PM, DevereB wrote:

    In your video, you indicate that there are no other treatments currently far along in the pipeline for Alzheimer's. What about PBT2 being developed by Prana (PRAN). First human testing was strongly successful with essentially no side effects and current studies are due to be completed in next few months, with recent clearance for continuation by safety monitoring committee, as well as approval for extension for all patients in the study after completion.

Add your comment.

DocumentId: 2536601, ~/Articles/ArticleHandler.aspx, 8/1/2014 11:17:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement